Valentina Gianfelici
YOU?
Author Swipe
View article: Correction: Niscola et al. Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies. Curr. Oncol. 2024, 31, 6632–6658
Correction: Niscola et al. Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies. Curr. Oncol. 2024, 31, 6632–6658 Open
In the original publication [...]
View article: Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias
Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias Open
Menin (MEN1) is a well-recognized powerful tumor promoter in acute leukemias (AL) with KMT2A rearrangements (KMT2Ar, also known as MLL) and mutant nucleophosmin 1 (NPM1m) acute myeloid leukemia (AML). MEN1 is essential for sustaining leuke…
View article: Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies Open
Acute myeloid leukemia (AML) is a heterogeneous blood-related neoplasm that predominantly afflicts older adults with a poor prognosis due to their physical condition and the presence of medical accompanying comorbidities, adverse biologica…
View article: Quality of life considerations in myelodysplastic syndrome: not only fatigue
Quality of life considerations in myelodysplastic syndrome: not only fatigue Open
KEYWORDS: myelodysplastic syndrome (MDS)quality of life (QOL)sleepphysical exerciselifestylepsychologyclinical treatment
View article: Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments
Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments Open
Acute myeloid leukemias (AMLs) are heterogeneous hematologic cancers that occur prevalently in older patients as the result of a complex pathobiology. The clinical outcomes of older patients with AML, often unsuitable for intensive chemoth…
View article: Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms
Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms Open
Myelodysplastic syndromes/neoplasms (MDSs) encompass a range of hematopoietic malignancies, commonly affecting elderly individuals. Molecular alterations in the hematopoietic stem cell compartment drive disease pathogenesis. Recent advance…
View article: BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study Open
no abstract available
View article: P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED, MULTICENTER STUDY.
P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED, MULTICENTER STUDY. Open
Background: Patients with chronic lymphocytic leukemia (CLL) show high infection-related morbidity and mortality due to variable degree of humoral and cellular immune deficiency. High Covid-related mortality and reduced response to the SAR…
View article: Contents Vol. 67, 2022
Contents Vol. 67, 2022 Open
View article: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study Open
Background: Antibody response following SARS-CoV-2 vaccination is somewhat defective in chronic lymphocytic leukemia (CLL). Moreover, the correlation between serologic response and status of cellular immunity has been poorly …
View article: A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine
A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine Open
Given the immunosuppression of chronic lymphocytic leukemia (CLL), this disease represents a challenging model for assessing the extent of serologic response to mRNA vaccination against severe Acute Respiratory Syndrome Coronavirus-2 (SARS…
View article: Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia Open
Introduction: Venetoclax has emerged as a breakthrough treatment which has revolutionized the therapeutic paradigm of chronic lymphocytic leukemia (CLL). This is primarily attributed to the efficacy of venetoclax as a time-limited, …
View article: Supplementary Material for: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study
Supplementary Material for: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study Open
Background: Antibody response following SARS-CoV2 vaccination is somewhat defective in chronic lymphocytic leukemia (CLL). Moreover, the correlation between serologic response and status of cellular immunity has been poorly studied. Object…
View article: Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia Open
To shed light onto the molecular basis of Philadelphia chromosome-positive acute lymphoblastic leukemia and to investigate the prognostic role of additional genomic lesions, we analyzed copy number aberrations using the Cytoscan HD Array i…
View article: Biological Aspects of mTOR in Leukemia
Biological Aspects of mTOR in Leukemia Open
The mammalian target of rapamycin (mTOR) is a central processor of intra- and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival. Strong evidences have indicated th…
View article: Rapid identification of <i><scp>BCR</scp>/<scp>ABL</scp>1</i>‐like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time‐polymerase chain reaction: clinical, prognostic and therapeutic implications
Rapid identification of <i><span>BCR</span>/<span>ABL</span>1</i>‐like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time‐polymerase chain reaction: clinical, prognostic and therapeutic implications Open
Summary BCR / ABL 1 ‐like acute lymphoblastic leukaemia ( ALL ) is a subgroup of B‐lineage acute lymphoblastic leukaemia that occurs within cases without recurrent molecular rearrangements. Gene expression profiling ( GEP ) can identify th…
View article: Clinical significance of recurrent copy number aberrations in B‐lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts
Clinical significance of recurrent copy number aberrations in B‐lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts Open
Summary Copy number aberrations ( CNA s) represent cooperating events in B‐lineage acute lymphoblastic leukaemia (B‐ ALL ); however, their clinical relevance across different age cohorts is unclear. We analysed the recurrent CNA s in 157 a…
View article: Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia
Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia Open
Recurrent deletions of the long arm of chromosome 5 were detected in 23/200 cases of T-cell acute lymphoblastic leukemia. Genomic studies identified two types of deletions: interstitial and terminal. Interstitial 5q deletions, found in fiv…
View article: RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications Open
Despite therapeutic improvements, a sizable number of patients with T-cell acute lymphoblastic leukemia still have a poor outcome. To unravel the genomic background associated with refractoriness, we evaluated the transcriptome of 19 cases…
View article: Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes Open
To shed light into the molecular bases of B-lineage acute lymphoblastic leukemia lacking known fusion transcripts, i.e. BCR-ABL1, ETV6-RUNX1, E2A-PBX1, and MLL rearrangements (B-NEG ALL) and the differences between children, adolescents/yo…
View article: A case of lineage switch from B‐cell acute lymphoblastic leukaemia to acute myeloid leukaemia. Role of subclonal/clonal gene mutations
A case of lineage switch from B‐cell acute lymphoblastic leukaemia to acute myeloid leukaemia. Role of subclonal/clonal gene mutations Open
We report the case of a patient with acute lymphoblastic leukaemia (ALL) who displayed a myeloid phenotype at relapse; the molecular IGH marker was conserved in the different phases of the disease. Next‐generation sequencing (NGS) analyses…
View article: CD45 antigen negativity in T-lineage ALL correlates with<i>PTPRC</i>mutation and sensitivity to a selective JAK inhibitor
CD45 antigen negativity in T-lineage ALL correlates with<i>PTPRC</i>mutation and sensitivity to a selective JAK inhibitor Open
The tyrosine phosphatase CD45 is a transmembrane protein encoded by the PTPRC gene, well known as a key regulator of B- and T-cell receptor signalling, which plays a role also as an inhibitor of JAK kinases (Irie-Sasaki et al, 2001; Saunde…